Tatyana A. Vetter

A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2

Kevin M. Flanigan, Tatyana A. Vetter, Tabatha R. Simmons et al. · Molecular Therapy — Methods & Clinical Development · 2022 · 31 citations · Full text

Osteosarcoma tumors maintain intra-tumoral transcriptional heterogeneity during bone and lung colonization

Sanjana Rajan, Emily Franz, Camille A. McAloney et al. · BMC Biology · 2023 · 31 citations · Full text

Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping

Tabatha R. Simmons, Tatyana A. Vetter, Nianyuan Huang et al. · Molecular Therapy — Methods & Clinical Development · 2021 · 27 citations · Full text

Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse

Nicolas Wein, Tatyana A. Vetter, Adeline Vulin et al. · Molecular Therapy — Methods & Clinical Development · 2022 · 26 citations · Full text

Duchenne Muscular Dystrophy, Immunology, Aav9 Exon-skipping Vector +5

Automated immunofluorescence analysis for sensitive and precise dystrophin quantification in muscle biopsies

Tatyana A. Vetter, Stefan Nicolau, A. Bradley et al. · Neuropathology and Applied Neurobiology · 2021 · 20 citations · Full text